Cannara Biotech Delivers Highest Revenue and Profitability Since Inception in Fiscal Q3 2025

Cannara Biotech Delivers Highest Revenue and Profitability Since Inception in Fiscal Q3 2025

Record Revenue: Total revenues, net of excise taxes increased to $27.3 million in Q3 2025, representing a 40% increase over the prior year period.Record Profitability: Gross profit before fair value adjustments rose to $12.1 million in Q3 2025, representing a…

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

July 25, 2025 16:15 ET  | Source: Portage Biotech Inc. DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) — Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands, with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today […] The post Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025 first …